The algorithm will help regulate a cardiac pacemaker based on the blood pressure in patients with HFpEF. Credit: peterschreiber.media / Shutterstock.com.

Medical device company BaroPace has enrolled the first patient in its non-pharmacologic hypertension and heart failure treatment trial evaluating PressurePace.

Dubbed RelieveHFpEF-II, the first-in-human clinical study has been designed to assess the effectiveness and safety of the PressurePace algorithm.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The real-time closed-loop pacemaker control algorithm is intended for regulating a cardiac pacemaker based on blood pressure in patients with heart failure with preserved ejection fraction (HFpEF).

The double-blind, multicentre, crossover study being conducted in India will enrol 16 subjects with HFpEF caused by hypertension.

It will compare standard pacemaker therapy, which includes rate adaptive pacing through a pacemaker accelerometer, with PressurePace.

Patients with stable blood pressure and body weight after one week of baseline measurements will be randomised to three weeks of standard pacemaker therapy versus PressurePace (BaroPacing).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In the treatment group (BaroPacing), pacemaker programming adjustments are carried out two times a day at the patient’s residence, while the standard treatment (placebo) group undergoes sham programming.

Improved exercise performance, safety and the Minnesota Living with Heart Failure Questionnaire are the primary endpoints of the study.

Atrial fibrillation incidences, frequency of hospitalisation and blood pressure control are the secondary endpoints.

BaroPace co-founder and CEO Michael Burnam said: “This milestone highlights our commitment to developing new, innovative non-pharmacologic technology that improves the quality of life and longevity of patients worldwide with resistant hypertension and HFpEF, two of the most important unmet needs in cardiovascular medicine.

“We look forward to the continued enrolment of subjects in RelieveHFpEF-II.”

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact